Together with fellow SmiLe Incubator alumni community member Cellevate, rAAVen Therapeutics announces the start of a shared project. Within this project rAAVen will design and

rAAVen Therapeutics announces the hiring of Yuriy Pomeshchik MD, PhD as Director of In Vitro. Before joining rAAVen, Yuriy held a position as Associate Researcher

rAAVen Therapeutics is pleased to share the news on our participation in this year’s  #ASGCT2024, and the symposium held by Myrtelle, Inc., where we will

rAAVen Therapeutics is excited to announce a new partnership with Prevail Therapeutics to develop novel adeno-associated virus (AAV) capsids for disorders of the nervous system. (link)

rAAVen Therapeutics has hired Magnus Henriks as the Chief Executive Officer. Prior to joining rAAVen, Magnus has had leading positions in various commercial companies. 

rAAVen Therapeutics has gone into an agreement, for a continuous partnership with Myrtelle, Inc. In the new collaboration rAAVen will validate a defined number of

Lena Mårtensson has been assigned to the rAAVen Therapeutics Board of Directors. Lena has an extensive background within Life Science, with multiple project and business

rAAVen Therapeutics will participate in the Viral Vector Formulation Process & Development Summit in Amsterdam 11-13 June. Our CSO, Patrick Aldrin-Kirk, will present the rAAVen

rAAVen Therapeutics is pleased to announce a new joint Photochemical Lysis project with PCI Biotech. In the project, rAAVen will develop and produce AAV, as

rAAVen Therapeutics hires Patrick Aldrin-Kirk, PhD as its new Chief Scientific Officer. Before joining rAAVen, Patrick did his postdoc and held a position as Associate